VYNE Therapeutics Inc VYNE 深 沪
等待开盘 07-10 09:30:00 美东时间
0.672
+0.022
+3.35%
华盛通- 最 高0.6789
- 今 开0.6585
- 成交量 2.70万股
- 最 低 0.6466
- 昨 收 0.6502
- 总市值 2243.48万
- 52周最高 1.595
- 市盈率 静 --
- 换手率 0.08%
- 52周最低 0.2805
- 委 比 -47.78%
- 总股本 3338.51万
- 历史最高 2869.92
- 量 比 0.10
- 振 幅 4.97%
- 历史最低 0.2805
- 每 手 1
- 风险率 0.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多VYNE Therapeutics Q1 EPS $(0.08) Beats $(0.18) Estimate, Sales $86.000K Miss $200.000K Estimate
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.18) by 55.56 percent. This is a 60 percent increase over losses of $(0.20) per share from
05-16 06:14
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Agape ATP (NASDAQ:ATPC) stock rose 68.1% to $0.15 during Wednesday's r...
2025-12-18 01:06
BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks
Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were sl...
2025-12-17 23:40
VYNE Therapeutics shares are trading higher after the company announced it entered into a definitive merger agreement pursuant to combine with Yarrow Bioscience.
VYNE Therapeutics shares are trading higher after the company announced it ente...
2025-12-17 21:32
BRIEF-Vyne Therapeutics And Yarrow Bioscience Announce Merger Agreement
Dec 17 (Reuters) - Vyne Therapeutics Inc VYNE.O: VYNE THERAPEUTICS AND YARROW BIOSCIENCE ANNOUNCE MERGER AGREEMENT VYNE THERAPEUTICS INC - COMBINED COMPANY TO TRADE UNDER TICKER 'YARW' VYNE THERAPEUTI...
2025-12-17 21:26
VYNE Therapeutics Q3 EPS $(0.17) Misses $(0.13) Estimate, Sales $169.000K Beat $100.000K Estimate
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. This is a 41.38 percent increase over losses of $(0.29) per share
2025-11-06 21:29
VYNE Therapeutics Q3 net loss narrows, strategic review ongoing
Overview VYNE Q3 net loss decreases compared to last year Company progressing with strategic review to maximize shareholder value Outlook VYNE is conducting a strategic review to explore options like ...
2025-11-06 21:07
Vyne Therapeutics reports third quarter results and updates on pipeline progress
Vyne Therapeutics Inc. reported a net loss of $7.3 million, or $0.17 per share, for the third quarter ended September 30, 2025, compared to a net loss of $12.2 million, or $0.29 per share, for the sam...
2025-11-06 21:05
VYNE Therapeutics Faces Nasdaq Non-Compliance Notice
VYNE Therapeutics ( ($VYNE) ) has shared an update. On September 11, 2025, VYNE...
2025-09-13 04:36
Vyne Therapeutics Receives Nasdaq Notification for Non-Compliance with Minimum Bid Price Rule
Vyne Therapeutics Inc. has announced that it received a notification from The Nasdaq Stock Market LLC regarding non-compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid...
2025-09-13 04:04
